Free Trial
NASDAQ:CLYM

Climb Bio Q4 2024 Earnings Report

Climb Bio logo
$1.18 -0.04 (-3.28%)
As of 04:00 PM Eastern

Climb Bio EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.15
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Climb Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Climb Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Tuesday, March 25, 2025
Conference Call Time
11:30AM ET

Upcoming Earnings

Climb Bio's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Climb Bio Earnings Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Climb Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email.

About Climb Bio

Climb Bio (NASDAQ:CLYM) Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

View Climb Bio Profile

More Earnings Resources from MarketBeat